ClinicalTrials.gg
CompletedNCT02077166Updated Feb 4, 2022Results posted

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 1/2 interventional study of Ibrutinib and Lenalidomide in Relapsed Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-04.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
138
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
5th of 26
138 · median 44
Started
2014
with 3 others
Phase 1/2
6 of 26
2 open now
Registered
6th of 26
by date
Lead sponsor
2 of 26
Pharmacyclics LLC.

Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 1/2, and was the 6th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.

Read the detailed description

Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses of lenalidomide may be explored, using the 3+3+3 principle for dose determination.

Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible subjects will receive ibrutinib, lenalidomide and rituximab.

03

Conditions studied

  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma

Keywords

  • DLBCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed DLBCL
  • Must have previously received treatment regimen
  • Must be ineligible for high dose therapy/ stem cell transplantation
  • sites on computed tomography (CT) scan (>1.5 cm in longest dimension)
  • /international normalized ratio (PT/INR) \< 1.5 x (ULN) and partial thromboplastin time (PTT; activated partial thromboplastin time [aPTT]) \<1.5 x ULN
  • Men and women ≥18 years of age
  • (ECOG) \< 2
  • Adequate hepatic and renal function
  • Adequate hematologic function

Exclusion criteria

Exclusion Criteria:

  • Medically apparent central nervous system lymphoma or
  • History of allogeneic stem-cell (or other organ) transplantation
  • Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks
  • Radio- or toxin-immunoconjugates within 10 weeks
  • Concurrent enrollment in another therapeutic study or have previously taken ibrutinib and/or lenalidomide.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)

    Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)

    De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)

    Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)

    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)

    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 2: Enrolled at Lenalidomide Dose 20 mg

    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Phase 2: Enrolled at Lenalidomide Dose 25 mg

    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

    The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion.

    Time frame: Estimated median time on study in Phase 1b was 59.6 months.

  2. Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs

    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0.

  3. Phase 2: Overall Response Rate (ORR)

    The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method.

    Time frame: Estimated median time on study in Phase 2 was 35.0 months.

Secondary outcomes

  1. Phase 1b: ORR

    The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method.

    Time frame: Estimated median time on study in Phase 1b was 59.6 months.

  2. Phase 1b: Complete Response (CR) Rate

    The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator.

    Time frame: Estimated median time on Phase 1b study was 59.6 months.

  3. Phase 2: CR Rate

    The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria) in response-evaluable population, as assessed by the Investigator.

    Time frame: Estimated median time on study in Phase 2 was 35.0 months.

  4. Phase 2: Duration of Response (DOR)

    DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method.

    Time frame: Estimated median time on study in Phase 2 was 35.0 months.

  5. Phase 2: Progression Free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method.

    Time frame: Estimated median time on study in Phase 2 was 35.0 months.

  6. Phase 2: Overall Survival (OS)

    OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method.

    Time frame: Estimated median time on study in Phase 2 was 35.0 months.

  7. Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs

    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug. Phase 2 median duration of ibrutinib exposure was 4.9 months; median duration of lenalidomide exposure was 4.7 months; median total number of doses of rituximab received was 5.0.

07

Results

Posted Feb 4, 2022

Participant flow

All participants had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In the Phase 1b portion of the study, all subtypes of DLBCL and participants with transformed disease were enrolled. In the Phase 2 portion of the study, only participants with non-germinal-center B-cell-like (non-GCB) DLBCL were enrolled.

Participant flow — Overall Study
MilestonePhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mg
Started1279985534
Completed0000000
Not completed1279985534
Withdrew: Death675643222
Withdrew: Study closure by sponsor30222124
Withdrew: Lost to follow-up0000010
Withdrew: Withdrawal by subject3011130
Withdrew: Other, not specified0010178

Outcome measures

PrimaryPhase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion.

Time frame:
Estimated median time on study in Phase 1b was 59.6 months.
Reported as:
Number · mg
Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
mgAll Phase 1b Participants
Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)20
PrimaryPhase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0.
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs
ParticipantsPhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
Any TEAE127998
Any Grade >=3 TEAE116997
Any Study Drug-Related TEAE125988
Any Grade >=3 Study Drug-Related TEAE103877
Any Ibrutinib-Related TEAE125988
Any Grade >=3 Ibrutinib-Related TEAE103776
Any Lenalidomide-Related TEAE125988
Any Grade >=3 Lenalidomide-Related TEAE93876
Any Rituximab-Related TEAE64767
Any Grade >= 3 Rituximab-Related TEAE12753
Any TEAE Leading to Dose Reduction of Any Study Drug40445
Any TEAE Leading to Dose Reduction of Ibrutinib30433
Any TEAE Leading to Dose Reduction of Lenalidomide20344
Any TEAE Leading to Dose Delay of Any Study Drug64788
Any TEAE Leading to Dose Delay of Ibrutinib64788
Any TEAE Leading to Dose Delay of Lenalidomide63778
Any TEAE Leading to Dose Delay of Rituximab41644
Any TEAE Leading to Discontinuation of Any Study Drug42321
Any TEAE Leading to Discontinuation of Ibrutinib Dose42321
Any TEAE Leading to Discontinuation of Lenalidomide Dose42321
Any TEAE Leading to Discontinuation of Rituximab Dose32321
Any Serious TEAE46756
Any Grade >=3 Serious TEAE46646
Any Treatment-Related Serious TEAE02423
Any Ibrutinib-Related Serious TEAE02423
Any Lenalidomide-Related Serious TEAE02423
Any Rituximab-Related Serious TEAE02210
Any Fatal TEAE02211
PrimaryPhase 2: Overall Response Rate (ORR)

The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method.

Time frame:
Estimated median time on study in Phase 2 was 35.0 months.
Reported as:
Number · percentage of participants
Phase 2: Overall Response Rate (ORR)
percentage of participantsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Phase 2: Overall Response Rate (ORR)52.8 (38.6 to 66.7)43.8 (26.4 to 62.3)49.4 (38.4 to 60.5)
SecondaryPhase 1b: ORR

The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method.

Time frame:
Estimated median time on study in Phase 1b was 59.6 months.
Reported as:
Number · percentage of participants
Phase 1b: ORR
percentage of participantsPhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels)
Phase 1b: ORR44.4 (13.7 to 78.8)0 (0 to 41.0)71.4 (29.0 to 96.3)22.2 (2.8 to 60.0)75.0 (34.9 to 96.8)42.5 (27.0 to 59.1)
SecondaryPhase 1b: Complete Response (CR) Rate

The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator.

Time frame:
Estimated median time on Phase 1b study was 59.6 months.
Reported as:
Number · percentage of participants
Phase 1b: Complete Response (CR) Rate
percentage of participantsPhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels)
Phase 1b: Complete Response (CR) Rate33.3042.911.150.027.5
SecondaryPhase 2: CR Rate

The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria) in response-evaluable population, as assessed by the Investigator.

Time frame:
Estimated median time on study in Phase 2 was 35.0 months.
Reported as:
Number · percentage of participants
Phase 2: CR Rate
percentage of participantsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Phase 2: CR Rate32.121.928.2
SecondaryPhase 2: Duration of Response (DOR)

DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method.

Time frame:
Estimated median time on study in Phase 2 was 35.0 months.
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Phase 2: Duration of Response (DOR)38.3 (3.7 to NA)28.6 (2.8 to 28.6)38.3 (9.5 to NA)
SecondaryPhase 2: Progression Free Survival (PFS)

PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method.

Time frame:
Estimated median time on study in Phase 2 was 35.0 months.
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS)
monthsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Phase 2: Progression Free Survival (PFS)5.4 (3.4 to 11.3)4.7 (2.6 to 24.8)5.4 (3.4 to 6.3)
SecondaryPhase 2: Overall Survival (OS)

OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method.

Time frame:
Estimated median time on study in Phase 2 was 35.0 months.
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Phase 2: Overall Survival (OS)14.7 (9.7 to 32.8)11.6 (5.7 to NA)14.2 (9.7 to 28.1)
SecondaryPhase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug. Phase 2 median duration of ibrutinib exposure was 4.9 months; median duration of lenalidomide exposure was 4.7 months; median total number of doses of rituximab received was 5.0.
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs
ParticipantsPhase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgPhase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
Any TEAE553489
Any Grade >=3 TEAE513081
Any Study Drug-Related TEAE523385
Any Grade >=3 Study Drug-Related TEAE412566
Any Ibrutinib-Related TEAE503282
Any Grade >=3 Ibrutinib-Related TEAE362460
Any Lenalidomide-Related TEAE513283
Any Grade >=3 Lenalidomide-Related TEAE402565
Any Rituximab-Related TEAE372562
Any Grade >= 3 Rituximab-Related TEAE181331
Any TEAE Leading to Dose Reduction of Any Study Drug231437
Any TEAE Leading to Dose Reduction of Ibrutinib12921
Any TEAE Leading to Dose Reduction of Lenalidomide211435
Any TEAE Leading to Dose Delay of Any Study Drug402969
Any TEAE Leading to Dose Delay of Ibrutinib382866
Any TEAE Leading to Dose Delay of Lenalidomide372663
Any TEAE Leading to Dose Delay of Rituximab10616
Any TEAE Leading to Discontinuation of Any Study Drug11718
Any TEAE Leading to Discontinuation of Ibrutinib Dose11516
Any TEAE Leading to Discontinuation of Lenalidomide Dose11718
Any TEAE Leading to Discontinuation of Rituximab Dose6410
Any Serious TEAE322557
Any Grade >=3 Serious TEAE292150
Any Treatment-Related Serious TEAE161228
Any Ibrutinib-Related Serious TEAE141226
Any Lenalidomide-Related Serious TEAE161026
Any Rituximab-Related Serious TEAE459
Any Fatal TEAE8412

Adverse events

Collected over All Cause Mortality Time Frame: Estimated median time on study in Phase 1b was 59.6 months. Estimated median time on study in Phase 2 was 35.0 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)7/12 (58.3%)4/12 (33.3%)12/12 (100%)
Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)7/7 (100%)6/7 (85.7%)7/7 (100%)
Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)5/9 (55.6%)7/9 (77.8%)9/9 (100%)
Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)7/9 (77.8%)5/9 (55.6%)9/9 (100%)
Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)5/8 (62.5%)6/8 (75%)8/8 (100%)
Phase 2: Enrolled at Lenalidomide Dose 20 mg33/55 (60%)32/55 (58.2%)54/55 (98.2%)
Phase 2: Enrolled at Lenalidomide Dose 25 mg22/34 (64.7%)25/34 (73.5%)34/34 (100%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventPhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mg
DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/122/71/92/91/85/553/34
CELLULITISInfections and infestations0/121/71/90/92/82/551/34
ANAEMIABlood and lymphatic system disorders0/120/72/90/90/81/550/34
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/120/70/92/91/80/552/34
ATRIAL FIBRILLATIONCardiac disorders0/120/71/92/91/81/551/34
PANCYTOPENIABlood and lymphatic system disorders0/121/70/90/90/80/550/34
BILE DUCT STENOSISHepatobiliary disorders0/121/70/90/90/80/550/34
FOLLICULITISInfections and infestations0/121/70/90/90/80/550/34
PNEUMONIAInfections and infestations0/121/71/90/90/83/552/34
SALMONELLA BACTERAEMIAInfections and infestations0/121/70/90/90/80/550/34
Most frequent other events
Showing 10 of 319
Most frequent other events
EventPhase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mg
DIARRHOEAGastrointestinal disorders9/123/73/94/97/832/5513/34
NEUTROPENIABlood and lymphatic system disorders5/120/76/93/95/825/5514/34
NAUSEAGastrointestinal disorders7/123/73/93/94/817/559/34
FATIGUEGeneral disorders6/123/75/92/93/822/5516/34
RASH MACULO-PAPULARSkin and subcutaneous tissue disorders2/121/75/93/92/815/5512/34
OEDEMA PERIPHERALGeneral disorders2/121/73/93/94/821/558/34
THROMBOCYTOPENIABlood and lymphatic system disorders4/122/74/94/93/811/5510/34
CONSTIPATIONGastrointestinal disorders5/122/74/94/93/811/5510/34
DECREASED APPETITEMetabolism and nutrition disorders2/121/74/92/92/88/555/34
PETECHIAESkin and subcutaneous tissue disorders1/120/70/94/92/85/552/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgTotal
Mean66.3 ± 13.1358.4 ± 7.6365.3 ± 13.4466.0 ± 8.6362.9 ± 14.2363.1 ± 11.7564.9 ± 12.5263.9 ± 11.88
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgTotal
Female43553231457
Male84445322077
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgTotal
Hispanic or Latino131000510
Not Hispanic or Latino1148985529124
Unknown or Not Reported00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)Phase 2: Enrolled at Lenalidomide Dose 20 mgPhase 2: Enrolled at Lenalidomide Dose 25 mgTotal
Asian00000123
Black or African American11101217
White1158975130121
Multiple Races00000011
Declined to Answer/Unknown01000102
08

Study locations

40 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Cedar Sinai Medical Center
    Los Angeles, California 90048, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Comprehensive Cancer Center of Nevada
    Las Vegas, Nevada 89169, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Summit Medical Group
    Morristown, New Jersey 07960, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • University of Cincinnati Health Barrett Center
    Cincinnati, Ohio 45267, United States
  • Mid-Ohio Oncology/ Hematology
    Columbus, Ohio 43219, United States
  • University of TN Medical Center
    Knoxville, Tennessee 37920, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Baylor Charles Sammons Cancer Center
    Dallas, Texas 75246, United States
  • The University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Medical Oncology Associates, PS
    Spokane, Washington 99208, United States
  • Northwest Medical Specialities, PLLC
    Tacoma, Washington 98405, United States
  • Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg
    Antwerpen, 2060, Belgium
  • CHU Brugmann
    Brussels, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Universiaetsklinikum Ulm
    Ulm, Baden-Wuerttemberg 89081, Germany
  • Klinikum der Universitaet Muenchen - Campus Grosshadern
    Muenchen, Bayern 81377, Germany
  • Klinikum rechts der Isar - Technische Universitaet Muenchen, III. Medizinische Klinik und Polyklinik
    Muenchen, Bayern 81675, Germany
  • Universitaetsklinikum Wuerzburg, Medizinische Klinik und Poliklinik II
    Wuerzburg, Bayern 97080, Germany
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, United Kingdom
  • University Hospital of Wales
    Cardiff, United Kingdom
  • Northwick Park Hospital
    Harrow, United Kingdom
  • The Leeds Teaching Hospitals
    Leeds, United Kingdom
  • Kings College Hospital
    London, United Kingdom
  • University College London Hospitals
    London, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, United Kingdom
09

References and documents

Publications

  • Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019 Sep 26;134(13):1024-1036. doi: 10.1182/blood.2018891598. Epub 2019 Jul 22. PubMed 31331917 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Dec 2020, 81 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 81 months is close to that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2014
First posted
Mar 4, 2014
StartActual
Mar 13, 2014
Primary completionActual
Dec 17, 2020
CompletionActual
Dec 17, 2020
Results first posted
Feb 4, 2022
Last update
Feb 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02077166
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 4, 2014
Start date
Mar 13, 2014
Primary completion
Dec 17, 2020
Completion
Dec 17, 2020
Results posted
Feb 4, 2022
Last update
Feb 4, 2022

Study contacts

Jutta K. Neuenburg, MD, PhD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Lenalidomide · Rituximab

Start the discussion